Kaushik Pandit

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (54)

• Efficacy and safety of fixed-dose dapagliflozin–pioglitazone in Indian adults with type 2 diabetes: a phase 3 PRO-1 trial
  Diabetology & Metabolic Syndrome 2026 DOI: 10.1186/s13098-026-02086-3
  +Save
• Diagnostic approach to rickets: an Endocrine Society of Bengal (ESB) consensus statement
  Annals of Pediatric Endocrinology & Metabolism 2024 DOI: 10.6065/apem.2448044.022
  +Save
• Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective
  Clinical Medicine Insights: Endocrinology and Diabetes 2024 DOI: 10.1177/11795514231203911
  +Save
• Insulin Access Enhancement in India: Expert Views on Integrating Interchangeable Biosimilar Insulin Glargine
  Cureus 2024 DOI: 10.7759/cureus.60983
  +Save
• Once-weekly Insulin Icodec as Compared to Once-daily Basal Insulins: A Meta-analysis
  Endocrine Practice 2024 DOI: 10.1016/j.eprac.2023.11.004
  +Save
• SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes
  The Journal of Clinical Endocrinology & Metabolism 2023 DOI: 10.1210/clinem/dgad113
  +Save
• Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
  Cureus 2023 DOI: 10.7759/cureus.39204
  +Save
• Diagnostic approach in 46, XY DSD: an endocrine society of bengal (ESB) consensus statement
  Journal of Pediatric Endocrinology and Metabolism 2022 DOI: 10.1515/jpem-2022-0515
  +Save
• Authors’ Response
  Endocrine Practice 2022 DOI: 10.1016/j.eprac.2022.07.013
  +Save
• Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?
  Endocrine Practice 2022 DOI: 10.1016/j.eprac.2022.05.005
  +Save